Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01922661 · ClinicalTrials.gov registry record · Phase 1
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
A Phase 1 study of Allergy, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01922661 is a Phase 1 study of Allergy that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 24 participants, below the 331-participant average among 15 other Allergy trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01922661, a Phase 1 study of Allergy, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of the study is to assess the safety and tolerability of single ascending doses of subcutaneously (SC) administered REGN1908-1909 in allergic, adult subjects.
Conditions Studied
Interventions
- OTHER placebo
- DRUG REGN1908-1909
Study Locations (2)
Kansas
- - Overland Park
Maryland
- - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01922661
The ClinicalTrials.gov registry entry for NCT01922661 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 15 other Allergy trials with a reported enrollment target (93% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01922661 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kansas, Maryland.
Frequently Asked Questions
What is clinical trial NCT01922661 about?
NCT01922661 is a clinical study titled "Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects". The primary objective of the study is to assess the safety and tolerability of single ascending doses of subcutaneously (SC) administered REGN1908-1909 in allergic, adult subjects.
What is the current status of trial NCT01922661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-08. Estimated completion is 2014-05.
What conditions does trial NCT01922661 study?
This clinical trial studies the following conditions: Allergy.
What interventions are being tested in trial NCT01922661?
The interventions under investigation include: placebo (OTHER), REGN1908-1909 (DRUG).
Who is sponsoring clinical trial NCT01922661?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01922661 being conducted?
This trial has 2 study locations across Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
COMPLETED · Phase 1
-
In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics
COMPLETED · Phase 1
-
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
RECRUITING
-
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
RECRUITING · Phase 4
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Childhood Allergy and the Neonatal Environment
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.